Immuron (ASX:IMC) tables 494pc increase in North American FY22 Travelan sales

Biopharmaceutical company Immuron (IMC) has seen a 494 per cent increase in North American Travelan sales for FY22. https://themarketherald.com.au/immuron-asximc-tables-494pc-increase-in-north-american-fy22-travelan-sales-2022-07-11/

This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.